Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28275300 | 1.00 | NR1I2 (0.55) | NR1I2MAPTALDH1A1POLBNAAA | |
| Hydrochloric Acid SCHEMBL29252979 | 0.98 | NR1I2 (0.54) | NR1I2MAPTALDH1A1POLBNAAA | |
| SCHEMBL19003601 | 0.98 | NR1I2 (0.53) | NR1I2MAPTALDH1A1POLBNAAA | |
| SCHEMBL3443068 | 0.92 | NR1I2 (0.46) | NR1I2MAPTALDH1A1POLBNAAA | |
| SCHEMBL9227674 | 0.92 | NR1I2 (0.46) | NR1I2MAPTALDH1A1POLBNAAA | |
| SCHEMBL18559615 | 0.92 | NR1I2 (0.46) | NR1I2MAPTALDH1A1POLBNAAA | |
| SCHEMBL18635879 | 0.92 | NR1I2 (0.46) | NR1I2MAPTALDH1A1POLBNAAA | |
| SCHEMBL21755116 | 0.92 | NR1I2 (0.46) | NR1I2MAPTALDH1A1POLBNAAA | |
| SCHEMBL18559449 | 0.92 | NR1I2 (0.46) | NR1I2MAPTALDH1A1POLBNAAA | |
| SCHEMBL9227794 | 0.92 | NR1I2 (0.46) | NR1I2MAPTALDH1A1POLBNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-11066414-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200123172-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | NR1I2 2341/4885MAPT 3547/4885ALDH1A1 3413/4885 |
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | NR1I2 1178/4885MAPT 3852/4885ALDH1A1 4531/4885 |
| US-20200123172-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | NR1I2 3846/4885MAPT 4689/4885ALDH1A1 2149/4885 |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NR1I2 1597/4885MAPT 2479/4885ALDH1A1 1806/4885 |
| US-11066414-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | NR1I2 3846/4885MAPT 4689/4885ALDH1A1 2149/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | NR1I2 2341/4885MAPT 3547/4885ALDH1A1 3413/4885 |
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | AHR, FURIN, CYP3A5 | NR1I2 65/4885MAPT 3156/4885ALDH1A1 375/4885 |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | NR1I2 983/4885MAPT 3534/4885ALDH1A1 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.